Physiomics PLC Collaborative Services Agreement (4257X)
26 April 2023 - 8:00AM
UK Regulatory
TIDMPYC
RNS Number : 4257X
Physiomics PLC
26 April 2023
26 April 2023
Physiomics plc
("Physiomics" or "the Company")
Collaborative Services Agreement
Physiomics plc (AIM: PYC), a leading mathematical modelling
company supporting oncology drug development and personalised
medicine solutions, announces the signature of a Collaborative
Services Agreement with ValiRx's wholly owned subsidiary Inaphaea
BioLabs Limited.
The agreement recognises the synergy between Inaphaea's growing
capabilities as a translational contract research organisation
(tCRO(R)) providing in-vitro laboratory-based services and
Physiomics' in-silico capabilities for advanced statistical
analyses, machine learning techniques, data handling and
visualisation, as well as biological modelling.
Under the agreement, service users of Inaphaea will be able to
benefit from Physiomics capabilities in a single service contract
with Inaphaea. Designed to offer a seamless integration of data
generation and data interpretation, this collaborative method of
working provides benefits to both companies as well as to the
service users.
Dr Jim Millen, CEO at Physiomics commented "The Collaborative
Service Agreement will expand the scope of our core consulting
business to discovery stage projects and improve our access to
clients focused on earlier stages of drug development, while at the
same time supporting Inaphaea's own service offering. The synergy
is clear and both the scientific and commercial ambitions of our
two companies are well matched. We look forward to working closely
with ValiRx through this initiative"
Dr Suzy Dilly, CEO at ValiRx explains "The Collaborative
Services Agreement is the first step towards converting Inaphaea
into a true tCRO(R). The Physiomics modelling skills will enable
our clients to interpret and build on the data generated within the
Inaphaea facility. I am delighted to be able to offer this
additional service module to our clients. This additional
value-added service will be available to our first service users,
with benefits expected to increase as more complex data generation
technologies are added to our capabilities"
This announcement is released by Physiomics plc and contains
inside information for the purposes of Article 7 of the Market
Abuse Regulation (EU) 596/2014 (MAR), and is disclosed in
accordance with the Company's obligations under Article 17 of
MAR.
Enquiries:
Physiomics plc
Dr Jim Millen, CEO
+44 (0)1865 784 980
Hybridan LLP (Broker)
Claire Louise Noyce
+44 (0) 203 764 2341
Strand Hanson Ltd (NOMAD)
James Dance & James Bellman
+44 (0)20 7409 3494
Notes for Editors
About Physiomics
Physiomics plc combines cutting edge PKPD and QSP modelling
techniques with cancer biology expertise, to help biotech and
pharma companies streamline their drug development journeys.
Our approach is to derive insight from all relevant data in
order to de-risk decision making and optimise design of
pre-clinical and clinical studies.
Through use of bespoke models and our proprietary Virtual Tumour
technology, the Physiomics team has informed the development of
over 100 projects, over 40 targets and 70 drugs. Clients include
Merck KGaA, Astellas, Bicycle Therapeutics, Numab Therapeutics
& CRUK.
About ValiRx
ValiRx is a life science company focused on early-stage cancer
therapeutics and women's health, accelerating the translation of
innovative science into impactful medicines to improve patient
lives.
ValiRx provides the scientific, financial, and commercial
framework for enabling rapid translation of innovative science into
clinical development.
Using its extensive and proven experience in research and drug
development, the team at ValiRx selects and incubates promising
novel drug candidates and guides them through an optimised process
of development, from pre-clinical studies to clinic and
investor-ready assets.
ValiRx connects diverse disciplines across scientific,
technical, and commercial domains, with the aim of achieving a more
streamlined, less costly, drug development process. The team works
closely with carefully selected collaborators and leverages the
combined expertise required for science to advance.
Lead candidates from ValiRx's portfolio are outlicensed or
partnered with investors through ValiRx subsidiary companies for
further clinical development and commercialisation.
ValiRx listed on the AIM Market of the London Stock Exchange in
October 2006 and trades under the ticker symbol: VAL.
For further information, visit: www.valirx.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
AGRDZGZDDKRGFZM
(END) Dow Jones Newswires
April 26, 2023 02:00 ET (06:00 GMT)
Physiomics (LSE:PYC)
Historical Stock Chart
Von Nov 2024 bis Dez 2024
Physiomics (LSE:PYC)
Historical Stock Chart
Von Dez 2023 bis Dez 2024
